Retour aux projets

35811.1 IP-LS

35811.1 IP-LS

Résumé

Preclinical development of innovative drug candidates for the treatment of glaucoma.

Textes supplémentaires

Abstract

Glaucoma is the second leading cause of blindness worldwide after cataracts. New treatments are needed to address a high unmet medical need. Our approach is to target neuroprotection by addressing two established risk factors as ocular blood flow and intraocular pressure.

Participants

Paola Atzei

Wirtschaftspartner

paola.atzei@topadur.com

Topadur Pharma AG CHE-481.951.668 Paola Atzei Grabenstrasse 11a 8952 Schlieren ZH CH

Christian Grimm

Kontaktperson

cgrimm@opht.uzh.ch

Universität Zürich Christian Grimm Wagistrasse 14 8952 Schlieren ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2019-09-30
Date de fin
2021-12-31
Coûts totaux approuvés
CHF 759834.50
Section
60 Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T410 Pharmaceuticals and related technologies 100.0%